Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

Cancer

Volumn 119, Issue 24, 2013, Pages 4223-4230

  Garrett, Christopher R ^a   Bekaii Saab, Tanios S ^b   Ryan, Theresa ^c   Fisher, George A ^d   Clive, Sally ^e   Kavan, Petr ^f   Shacham Shmueli, Einat ^g   Buchbinder, Aby ^h   Goldberg, Richard M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h Enzon Incorporated   (United States)

Author keywords

colorectal cancer; EZN 2208; pegylated; randomized phase 2; SN 38

Indexed keywords

ALKALINE PHOSPHATASE; CETUXIMAB; DOXYCYCLINE; FIRTECAN PEGOL; FLUOROURACIL; HYDROCORTISONE; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER INFECTION; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; HYPONATREMIA; KRAS GENE; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTANT; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; YOUNG ADULT;

COLORECTAL CANCER; EZN-2208; PEGYLATED; RANDOMIZED PHASE 2; SN-38;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; YOUNG ADULT;

EID: 84889882607     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28358     Document Type: Article

References (29)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
2. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-1418.
3. Rothenberg ML, Kuhn JG, Burris HA III, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993; 11: 2194-2204.
4. Pasut G, Veronese FM,. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev. 2009; 61: 1177-1188.
5. Crawford J,. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol. 2003; 30: 24-30.
6. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
7. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372: 117-126.
8. Zhao H, Rubio B, Sapra P, et al. Novel prodrugs of SN38 using multi-arm polyethylene glycol (PEG) linkers. Bioconjug Chem. 2008; 19: 849-859.
9. Sapra P, Zhao H, Mehlig M, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14: 1888-1896.
10. Pastorino F, Loi M, Sapra P, et al. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res. 2010; 16: 4809-4821.
11. Sapra P, Kraft P, Mehlig M, et al. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica. 2009; 94: 1456-1459.
12. Sapra P, Kraft P, Pastorino F, et al. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis. 2011; 14: 245-253.
13. Kurzrock R, Goel S, Wheler J, et al. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012; 118: 6144-6151.
14. Patnaik A, Papadopoulos KP, Beeram M, et al. EZN-2208, a novel anticancer agent, in patients with advanced malignancies: a phase 1 dose-escalation study [abstract]. Mol Cancer Ther. 2009; 8 (12 suppl 1). Abstract C22.
15. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S,. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006; 12: 313-325.
16. Fang J, Nakamura H, Maeda H,. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011; 63: 136-151.
17. Caliceti P, Veronese FM,. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003; 55: 1261-1277.
18. Zander SA, Sol W, Greenberger L, et al. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors [serial online]. PloS One. 2012; 7: e45248.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
20. Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer. 2011; 10: 333-339.
21. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 2311-2319.
22. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 3.0. Bethesda, MD: Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2003.
23. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25: 3230-3237.
24. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
25. Tripathi S, Zhao H, Wu D, et al. Customized PEG linkers improve the pharmaceutical properties of cytotoxic small molecules [abstract]. Paper presented at: 10III Annual Meeting of the American Association for Cancer Research; April 17-1, 2010; Washington, DC.
26. Greenwald RB, Zhao H,. Poly(ethylene glycol) prodrugs: altered pharmacokinetics and pharmacodynamics. In:, Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW, eds. Prodrugs: Challenges and Rewards, part 1. Series: Biotechnology: Pharmaceutical Aspects. New York: Springer; 2007: 283-338.
27. Osborne CRC, O'Shaughnessy J, Holmes FA, et al. Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 1017.
28. Norris R, Shusterman S, Gore L, et al. Phase I trial of polyethylene glycol (PEG) conjugated SN38 in children with recurrent or refractory neuroblastoma and other solid tumors [abstract]. Paper presented at: Advances in Neuroblastoma Research Association 2010 Conference; June 21-24, 2010; Stockholm, Sweden.
29. National Institutes of Health. EZN-2208 (pegylated SN-38) in combination with bevacizumab in refractory solid tumors. Sponsored by the National Cancer Institute. Available at: http://clinicaltrials.gov/ct2/show/NCT01251926. Accessed February 18, 2013.